还原型谷胱甘肽对乙肝肝硬化患者的影响
|
摘要
目的探讨还原型谷胱甘肽对乙型肝炎肝硬化患者肝纤维化及肝功能的影响。方法收集2015年5月—2018年1月我院收治的乙型肝炎肝硬化患者100例作为研究对象,将其随机分为研究组与对照组。两组患者基础治疗均相同,研究组加用还原型谷胱甘肽治疗。对比两组患者治疗前后肝纤维化指标(TGF-β1、TNF-α、层粘连蛋白、Ⅲ型前胶原N端肽)及肝功能(谷丙转氨酶、谷草转氨酶、γ-谷氨酰转肽酶)变化。结果治疗前,两组患者的肝纤维化指标比较,差异无统计学意义(P> 0.05);治疗后,研究组患者的肝纤维化指标低于对照组,差异有统计学意义(P <0.05);两组治疗前肝功能指标比较,差异无统计学意义(P> 0.05);研究组患者治疗后肝功能指标低于对照组,差异具有统计学意义(P <0.05)。结论给予乙型肝炎肝硬化患者还原型谷胱甘肽治疗,可以改善患者肝纤维化程度,促进肝脏细胞的修复。
Objective To investigate the effect of reduced glutathione on hepatic fibrosis and liver function in patients with hepatitis B cirrhosis.Methods 100 patients with hepatitis B cirrhosis admitted to our hospital from May 2015 to January 2018 were collected as the research objects.They were randomly divided into study group and control group. The basic treatment was the same in both groups. The study group was treated with reduced glutathione. The changes of liver fibrosis indexes(TGF-β1, TNF-α,laminin, N-terminal peptide of type Ⅲ procollagen) and liver function(alanine aminotransferase, glutathione aminotransferase and γ-glutamyl transpeptidase)were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference in liver fibrosis indexes between the two groups(P > 0.05). After treatment, the index of liver fibrosis in the study group was lower than that in the control group(P < 0.05). There was no significant difference in liver function between the two groups before treatment(P > 0.05). The indexes of liver function in the study group were lower than those in the control group after treatment, and the difference was statistically significant(P < 0.05). Conclusion The treatment of reduced glutathione in patients with hepatitis B cirrhosis can improve the degree of liver fibrosis and promote the repair of liver cells.
Objective To investigate the effect of reduced glutathione on hepatic fibrosis and liver function in patients with hepatitis B cirrhosis.Methods 100 patients with hepatitis B cirrhosis admitted to our hospital from May 2015 to January 2018 were collected as the research objects.They were randomly divided into study group and control group. The basic treatment was the same in both groups. The study group was treated with reduced glutathione. The changes of liver fibrosis indexes(TGF-β1, TNF-α,laminin, N-terminal peptide of type Ⅲ procollagen) and liver function(alanine aminotransferase, glutathione aminotransferase and γ-glutamyl transpeptidase)were compared between the two groups before and after treatment. Results Before treatment, there was no significant difference in liver fibrosis indexes between the two groups(P > 0.05). After treatment, the index of liver fibrosis in the study group was lower than that in the control group(P < 0.05). There was no significant difference in liver function between the two groups before treatment(P > 0.05). The indexes of liver function in the study group were lower than those in the control group after treatment, and the difference was statistically significant(P < 0.05). Conclusion The treatment of reduced glutathione in patients with hepatitis B cirrhosis can improve the degree of liver fibrosis and promote the repair of liver cells.
引文
[1]侯保全.复方甘草酸苷联合还原型谷胱甘肽对酒精性肝硬化患者肝功能指标的影响[J].临床研究,2018,26(9):32-33.
[2]李锐,姜东莉,李忻.还原型谷胱甘肽致严重不良反应1例[J].中国实验诊断学,2018,22(8):1430-1431.
[3]张淑君.还原型谷胱甘肽联合常规西药治疗乙型病毒性肝炎的效果观察[J].医学理论与实践,2018,31(16):2422-2424.
[4]徐云.复方甘草酸苷联合还原型谷胱甘肽对酒精性肝硬化肝功能及肝纤维化的影响[J].卫生职业教育,2018,36(16):139-141.
[5]王双豹,韩永燕,李佳,等.还原型谷胱甘肽对急性重度一氧化碳中毒伴心肌损伤的疗效[J].贵州医科大学学报,2018,43(8):958-961.
[6]汪志强,康金科,周庆,等.益气活血通络汤联合还原型谷胱甘肽对腹腔镜结直肠癌根治术后患者肝功能及炎性-应激状态的影响[J].现代中西医结合杂志,2018,27(24):2634-2637,2641.
[7]戴森茂.还原型谷胱甘肽预防他汀类药物致乙肝患者肝损害效果观察[J].临床合理用药杂志,2018,11(22):86-87.
[8]杨梅.促肝细胞生长素联合还原型谷胱甘肽治疗新生儿肝损害疗效观察[J].世界最新医学信息文摘(连续型电子期刊),2018,18(64):68,75.
[9]王玉乐,樊欢欢,向国强,等.基于碳量子点修饰纳米硅胶荧光猝灭-恢复测定粮食样品中还原型谷胱甘肽[J].化学研究,2017,28(5):633-638.
[10]杨常菀,巴清云,张志新,等.双环醇联合还原型谷胱甘肽治疗抗结核药物性肝炎的临床研究[J].现代药物与临床,2017,32(4):653-656.
[11]赵铜超.还原型谷胱甘肽在二噁英致腭裂模型中的作用研究[D].济南:山东大学,2017:12.
[12]方林,魏宁,徐浩,等.还原型谷胱甘肽在原发性肝癌介入治疗后保肝作用中的临床应用[J].介入放射学杂志,2017,26(2):169-172.
[2]李锐,姜东莉,李忻.还原型谷胱甘肽致严重不良反应1例[J].中国实验诊断学,2018,22(8):1430-1431.
[3]张淑君.还原型谷胱甘肽联合常规西药治疗乙型病毒性肝炎的效果观察[J].医学理论与实践,2018,31(16):2422-2424.
[4]徐云.复方甘草酸苷联合还原型谷胱甘肽对酒精性肝硬化肝功能及肝纤维化的影响[J].卫生职业教育,2018,36(16):139-141.
[5]王双豹,韩永燕,李佳,等.还原型谷胱甘肽对急性重度一氧化碳中毒伴心肌损伤的疗效[J].贵州医科大学学报,2018,43(8):958-961.
[6]汪志强,康金科,周庆,等.益气活血通络汤联合还原型谷胱甘肽对腹腔镜结直肠癌根治术后患者肝功能及炎性-应激状态的影响[J].现代中西医结合杂志,2018,27(24):2634-2637,2641.
[7]戴森茂.还原型谷胱甘肽预防他汀类药物致乙肝患者肝损害效果观察[J].临床合理用药杂志,2018,11(22):86-87.
[8]杨梅.促肝细胞生长素联合还原型谷胱甘肽治疗新生儿肝损害疗效观察[J].世界最新医学信息文摘(连续型电子期刊),2018,18(64):68,75.
[9]王玉乐,樊欢欢,向国强,等.基于碳量子点修饰纳米硅胶荧光猝灭-恢复测定粮食样品中还原型谷胱甘肽[J].化学研究,2017,28(5):633-638.
[10]杨常菀,巴清云,张志新,等.双环醇联合还原型谷胱甘肽治疗抗结核药物性肝炎的临床研究[J].现代药物与临床,2017,32(4):653-656.
[11]赵铜超.还原型谷胱甘肽在二噁英致腭裂模型中的作用研究[D].济南:山东大学,2017:12.
[12]方林,魏宁,徐浩,等.还原型谷胱甘肽在原发性肝癌介入治疗后保肝作用中的临床应用[J].介入放射学杂志,2017,26(2):169-172.